Walleye Capital
RLMD icon

Walleye Capital’s Relmada Therapeutics RLMD Stock Holding History

Walleye Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-262,481
Closed -$593K – 4808
2023
Q1 		$593K Sell
262,481
-211,202
-45% -$728K 0.01% 1573
2022
Q4 		$1.65M Buy
+473,683
New +$4.16M 0.03% 686
2022
Q3 		– Sell
-106,420
Closed -$2.95M – 3491
2022
Q2 		$2.02M Sell
106,420
-16,809
-14% -$367K 0.06% 362
2022
Q1 		$3.33M Buy
123,229
+102,410
+492% +$2.12M 0.09% 236
2021
Q4 		$469K Buy
+20,819
New +$463K 0.01% 1027

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Walleye Capital's RLMD Position: Q2 2023 in Review

Walleye Capital sold out of Relmada Therapeutics (RLMD) in Q2 2023, closing a stake of 262,481 shares — an estimated $593K sold.

Walleye Capital first reported a position in RLMD in Q4 2021 and held it in 5 quarters. The position peaked at $3.33M in Q1 2022. 95 funds tracked by Wall St. Rank hold RLMD as of Q2 2023.

  • Walleye Capital reported no remaining Relmada Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Walleye Capital sold 262,481 Relmada Therapeutics shares in Q2 2023, an estimated $593K.
  • Walleye Capital first reported a position in Relmada Therapeutics in Q4 2021 and held it in 5 quarters.
  • Walleye Capital's Relmada Therapeutics position peaked at $3.33M in Q1 2022.
  • 95 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2023.

Based on Walleye Capital's 13F filing for Q2 2023, filed 14 Aug 2023.